Abstract
In the first part of this review studies are considered in which pre- or post-training peripheral or intracerebroventricular administrations of competitive or noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonists were carried out in a variety of animal species tested in different experimental conditions, in order to investigate the effects of these drugs on acquisition and memory processes. In particular, post-training treatments, which are known to affect memory consolidation, ruling out the possible aspecific effects linked to the pre-training administrations, show that the NMDA receptor antagonists impair memory in animals tested in various tasks. Memory impairments are also evident when the NMDA antagonists (in particular AP5) are injected into different brain structures, including amygdala and hippocampus. In a second part of this review some recent studies are considered showing the existence of: a) cholinergic-glutamatergic interactions; b) interactions between NMDA receptors and opioid system, and c) interactions between NMDA receptor antagonists (MK-801) and cocaine, in the modulation of memory processes of laboratory animals. The results of some studies showing the involvement of glutamatergic mechanisms in Alzheimers disease are finally reported, and the therapeutic efficacy of glutamatergic drugs in the treatment of this disease is considered.
Keywords: NMDA Receptors, glutamatergic drugs, 2-amino-5-phosphonopentanoic acid, intrahippocampal infusions, MK-801
Current Drug Targets
Title: NMDA Receptors and Learning and Memory Processes
Volume: 2 Issue: 3
Author(s): C. Castellano, V. Cestari and A. Ciamei
Affiliation:
Keywords: NMDA Receptors, glutamatergic drugs, 2-amino-5-phosphonopentanoic acid, intrahippocampal infusions, MK-801
Abstract: In the first part of this review studies are considered in which pre- or post-training peripheral or intracerebroventricular administrations of competitive or noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonists were carried out in a variety of animal species tested in different experimental conditions, in order to investigate the effects of these drugs on acquisition and memory processes. In particular, post-training treatments, which are known to affect memory consolidation, ruling out the possible aspecific effects linked to the pre-training administrations, show that the NMDA receptor antagonists impair memory in animals tested in various tasks. Memory impairments are also evident when the NMDA antagonists (in particular AP5) are injected into different brain structures, including amygdala and hippocampus. In a second part of this review some recent studies are considered showing the existence of: a) cholinergic-glutamatergic interactions; b) interactions between NMDA receptors and opioid system, and c) interactions between NMDA receptor antagonists (MK-801) and cocaine, in the modulation of memory processes of laboratory animals. The results of some studies showing the involvement of glutamatergic mechanisms in Alzheimers disease are finally reported, and the therapeutic efficacy of glutamatergic drugs in the treatment of this disease is considered.
Export Options
About this article
Cite this article as:
Castellano C., Cestari V. and Ciamei A., NMDA Receptors and Learning and Memory Processes, Current Drug Targets 2001; 2 (3) . https://dx.doi.org/10.2174/1389450013348515
DOI https://dx.doi.org/10.2174/1389450013348515 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Chronic Stress Impacts on Olfactory System
CNS & Neurological Disorders - Drug Targets Pharmacogenetics and Anaesthesiology
Current Pharmacogenomics Millennium Nutrient N,N-Dimethylglycine (DMG) and its Effectiveness in Autism Spectrum Disorders
Current Medicinal Chemistry Heart Rate Variability Based Prediction of Personalized Drug Therapeutic Response: The Present Status and the Perspectives
Current Topics in Medicinal Chemistry Immunoproteasome in Cancer and Neuropathologies: A New Therapeutic Target?
Current Pharmaceutical Design The Effects of Obesity on Drug Metabolism in Children
Drug Metabolism Letters Hybrid Imaging: Conclusions and Perspectives
Current Medical Imaging The Gastrin-Releasing Peptide Receptor as a Therapeutic Target in Central Nervous System Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Coenzyme Q10 and Neurological Diseases: An Update
Letters in Drug Design & Discovery Coumarin-1,2,3-triazole Hybrid Molecules: An Emerging Scaffold for Combating Drug Resistance
Current Topics in Medicinal Chemistry Editorial (Thematic Issue: Mental Diseases in Medicinal Chemistry: From Synthetic and Natural Drugs to their Therapeutic Treatments)
Current Topics in Medicinal Chemistry Transient Receptor Potential Vanilloid 1 and Xenobiotics
CNS & Neurological Disorders - Drug Targets Impaired Functional Connectivity of the Thalamus in Alzheimer’ s Disease and Mild Cognitive Impairment: A Resting-State fMRI Study
Current Alzheimer Research Immunomodulatory Properties of Antibiotics
Current Molecular Pharmacology Recent Progress in the Pharmacology of Imidazo[1,2-a]pyridines
Mini-Reviews in Medicinal Chemistry Phosphodiesterase as a Target for Cognition Enhancement in Schizophrenia
Current Topics in Medicinal Chemistry Influence of CYP3A5 Polymorphism on the Pharmacokinetics of Psychiatric Drugs
Current Drug Metabolism The Hippocampal Autophagic Machinery is Depressed in the Absence of the Circadian Clock Protein PER1 that may Lead to Vulnerability During Cerebral Ischemia
Current Neurovascular Research Assessment of Memory Impairment in Early Diagnosis of Alzheimer’s Disease
Current Alzheimer Research Imaging Features and Misdiagnosis of Giant Cerebral Cavernous Malformations
Current Medical Imaging